Trial of Yellow 577 nm Laser Versus Green 532 nm Laser for Proliferative Diabetic Retinopathy
NCT ID: NCT01044875
Last Updated: 2010-01-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
120 participants
INTERVENTIONAL
2009-09-30
2011-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study also compares pain score of patients receiving laser treatment and side effects of laser treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Micropulse 577 nm Laser Photocoagulation Versus Conventional 532 nm Laser Photocoagulation for Diabetic Macular Oedema
NCT01045239
577nm Micropulse Laser Versus 532nm Subthreshold Laser Photocoagulation for Diabetic Macular Edema
NCT02406157
Comparison of Different Fluence Settings for Yellow Subthreshold Laser Treatment in Diabetic Macular Edema
NCT03571659
Navigation Laser Versus Traditional Laser Photocoagulation for Mild Diabetic Macular Edema
NCT03641144
Safety and Effectiveness Study of 532nm Laser Subthreshold Panretinal Photocoagulation for Severe NPDR
NCT01759121
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Panretinal photocoagulation is established as the gold standard of treatment, supported by the data of the Diabetic Retinopathy Study (DRS).This study found that laser treatment reduced the rate of severe visual loss by 50%. Currently the green 532nm laser is the most common wavelength used. However, this conventional green laser has some complications such as pain, vitreous haemorrhage, choroidal effusion and visual field loss.
Due to the complication of conventional lasers, the yellow laser (577 nm)with peak absorption of oxyhemoglobin and good absorption of melanin is postulated to be more effective at producing retinal laser burns with a lower power and less pain compared to the green laser.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
green laser 532 nm conventional
Current type of laser used for treatment of proliferative diabetic retinopathy
Pan retinal photocoagulation laser treatment
Eyes with PDR are randomised to treatment with either the green laser 532 nm or 577 nm yellow laser.
Yellow 577 nm laser
new laser wavelength for treatment of PDR
Pan retinal photocoagulation laser treatment
Eyes with PDR are randomised to treatment with either the green laser 532 nm or 577 nm yellow laser.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pan retinal photocoagulation laser treatment
Eyes with PDR are randomised to treatment with either the green laser 532 nm or 577 nm yellow laser.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Eyes with proliferative diabetic retinopathy requiring laser PRP
* Newly diagnosed patient
* Patients with no other intervention/surgeries done before the study
Exclusion Criteria
* Patients who have had previous laser photocoagulation
* Patients who have had previous vitreoretinal surgery
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Malaya
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of Malaya
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kenneth C Fong, FRCOphth
Role: PRINCIPAL_INVESTIGATOR
University of Malaya Eye Research Centre
Nurliza Khaliddin, FRCS
Role: PRINCIPAL_INVESTIGATOR
University of Malaya Eye Research Centre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Malaya Eye Research Centre
Kuala Lumpur, Kuala Lumpur, Malaysia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UMERC002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.